The emerging sarcopenia pipeline has advanced to Phase II, led by monoclonal antibody candidates that block activation of proteins associated with skeletal muscle loss.
Novartis AG, Eli Lilly & Co., and the partnership of Sanofi and Regeneron Pharmaceuticals Inc. are...